Candid Therapeutics /
Rallybio
Candid Therapeutics agrees to buy Rallybio




Source for the buyer and target: Rallybio Corp
For the buyer and target.
“On March 1, 2026, Rallybio Corporation, a Delaware corporation (“ Rallybio ”), entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement ”) with Candid Therapeutics, Inc., a Delaware corporation (“ Candid ”), a clinical-stage biotechnology company advancing a leading portfolio of T-cell engager (TCE) therapeutics for autoimmune diseases, and Farmington Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Rallybio (“ Merger Sub ”).”
Published 2 Mar 2026
Open the sourceWhat happened
Candid Therapeutics agreed to acquire Rallybio, according to a filing dated March 2, 2026. [01]
The source
Everything on this page comes from the source below, quoted word for word.
Candid Therapeutics agrees to buy Rallybio
This document is the source for the companies, stage and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
Announced
“Candid Therapeutics agrees to buy Rallybio Candid Therapeutics agreed to acquire Rallybio, according to a filing dated March 2, 2026”
Open the source
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly